{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:50:03Z","timestamp":1773939003851,"version":"3.50.1"},"reference-count":121,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NCI R21","doi-asserted-by":"publisher","award":["1R21CA252010-01A1"],"award-info":[{"award-number":["1R21CA252010-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"HFHS Research Administration Start Up","award":["1R21CA252010-01A1"],"award-info":[{"award-number":["1R21CA252010-01A1"]}]},{"name":"HFHS Proposal Development Award","award":["1R21CA252010-01A1"],"award-info":[{"award-number":["1R21CA252010-01A1"]}]},{"name":"Game on Cancer Award","award":["1R21CA252010-01A1"],"award-info":[{"award-number":["1R21CA252010-01A1"]}]},{"name":"HFHS-Radiation Oncology Start Up to Shyam Nyati","award":["1R21CA252010-01A1"],"award-info":[{"award-number":["1R21CA252010-01A1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Pancreatic cancer presents formidable challenges due to rapid progression and resistance to conventional treatments. Oncolytic viruses (OVs) selectively infect cancer cells and cause cancer cells to lyse, releasing molecules that can be identified by the host\u2019s immune system. Moreover, OV can carry immune-stimulatory payloads such as interleukin-12, which when delivered locally can enhance immune system-mediated tumor killing. OVs are very well tolerated by cancer patients due to their ability to selectively target tumors without affecting surrounding normal tissues. OVs have recently been combined with other therapies, including chemotherapy and immunotherapy, to improve clinical outcomes. Several OVs including adenovirus, herpes simplex viruses (HSVs), vaccinia virus, parvovirus, reovirus, and measles virus have been evaluated in preclinical and clinical settings for the treatment of pancreatic cancer. We evaluated the safety and tolerability of a replication-competent oncolytic adenoviral vector carrying two suicide genes (thymidine kinase, TK; and cytosine deaminase, CD) and human interleukin-12 (hIL12) in metastatic pancreatic cancer patients in a phase 1 trial. This vector was found to be safe and well-tolerated at the highest doses tested without causing any significant adverse events (SAEs). Moreover, long-term follow-up studies indicated an increase in the overall survival (OS) in subjects receiving the highest dose of the OV. Our encouraging long-term survival data provide hope for patients with advanced pancreatic cancer, a disease that has not seen a meaningful increase in OS in the last five decades. In this review article, we highlight several preclinical and clinical studies and discuss future directions for optimizing OV therapy in pancreatic cancer. We envision OV-based gene therapy to be a game changer in the near future with the advent of newer generation OVs that have higher specificity and selectivity combined with personalized treatment plans developed under AI guidance.<\/jats:p>","DOI":"10.3390\/ijms25189912","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T11:29:59Z","timestamp":1726226999000},"page":"9912","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Optimizing Pancreatic Cancer Therapy: The Promise of Immune Stimulatory Oncolytic Viruses"],"prefix":"10.3390","volume":"25","author":[{"given":"Shivani","family":"Thoidingjam","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Henry Ford Health, Detroit, MI 48202, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5188-3696","authenticated-orcid":false,"given":"Aseem Rai","family":"Bhatnagar","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Henry Ford Health, Detroit, MI 48202, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushmitha","family":"Sriramulu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Henry Ford Health, Detroit, MI 48202, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzan","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Henry Ford Health, Detroit, MI 48202, USA"},{"name":"Henry Ford Health + Michigan State University Health Sciences, Detroit, MI 48202, USA"},{"name":"Department of Medicine, Michigan State University, East Lansing, MI 48824, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1435-303X","authenticated-orcid":false,"given":"Shyam","family":"Nyati","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Henry Ford Health, Detroit, MI 48202, USA"},{"name":"Henry Ford Health + Michigan State University Health Sciences, Detroit, MI 48202, USA"},{"name":"Department of Radiology, Michigan State University, East Lansing, MI 48824, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12957-021-02478-x","article-title":"Prognosis and survival analysis of patients with pancreatic cancer: Retrospective experience of a single institution","volume":"20","author":"Li","year":"2022","journal-title":"World J. Surg. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Carvalho, T.M.A., Di Molfetta, D., Greco, M.R., Koltai, T., Alfarouk, K.O., Reshkin, S.J., and Cardone, R.A. (2021). Tumor Microenvironment Features and Chemoresistance in Pancreatic Ductal Adenocarcinoma: Insights into Targeting Physicochemical Barriers and Metabolism as Therapeutic Approaches. Cancers, 13.","DOI":"10.3390\/cancers13236135"},{"key":"ref_4","unstructured":"Puckett, Y., and Garfield, K. (2024, August 09). Pancreatic Cancer, StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK518996\/."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"S\u0142odkowski, M., Wro\u0144ski, M., Karkocha, D., Kraj, L., \u015amigielska, K., and Jachnis, A. (2023). Current Approaches for the Curative-Intent Surgical Treatment of Pancreatic Ductal Adenocarcinoma. Cancers, 15.","DOI":"10.3390\/cancers15092584"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1200\/JCO.2017.72.6463","article-title":"CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial","volume":"35","author":"Sinn","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Ervin","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"15283","DOI":"10.1007\/s13277-016-5321-6","article-title":"Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer","volume":"37","author":"Liu","year":"2016","journal-title":"Tumour Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/path.5906","article-title":"Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment","volume":"257","author":"Hennig","year":"2022","journal-title":"J. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1001\/jamaoncol.2019.0684","article-title":"Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial","volume":"5","author":"Karasic","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"524","DOI":"10.4161\/cbt.4.5.1820","article-title":"Viral oncolysis by herpes simplex virus and other viruses","volume":"4","author":"Kuruppu","year":"2005","journal-title":"Cancer Biol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s12094-012-0951-7","article-title":"Viruses in cancer treatment","volume":"15","author":"Alemany","year":"2013","journal-title":"Clin. Transl. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Tan, S., Li, D., and Zhu, X. (2020). Cancer immunotherapy: Pros, cons and beyond. Biomed. Pharmacother., 124.","DOI":"10.1016\/j.biopha.2020.109821"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-020-00922-1","article-title":"Oncolytic viruses for cancer immunotherapy","volume":"13","author":"Hemminki","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s41231-023-00144-w","article-title":"Oncolytic virus-based suicide gene therapy for cancer treatment: A perspective of the clinical trials conducted at Henry Ford Health","volume":"8","author":"Thoidingjam","year":"2023","journal-title":"Transl. Med. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1158\/1078-0432.CCR-05-1595","article-title":"Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus","volume":"12","author":"Ochiai","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Marintcheva, B. (2018). Chapter 9\u2014Virus-based therapeutic approaches. Harnessing the Power of Viruses, Academic Press.","DOI":"10.1016\/B978-0-12-810514-6.00009-X"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/1759-7714.13043","article-title":"Updates to the antitumor mechanism of oncolytic virus","volume":"10","author":"Bai","year":"2019","journal-title":"Thorac. Cancer."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Marelli, G., Howells, A., Lemoine, N.R., and Wang, Y. (2018). Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00866"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: A new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1186\/s12967-023-04360-8","article-title":"Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy","volume":"21","author":"Wang","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ymthe.2020.10.027","article-title":"Reshaping the Immune Microenvironment by Oncolytic Herpes Simplex Virus in Murine Pancreatic Ductal Adenocarcinoma","volume":"29","author":"Zhang","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Mantwill, K., Klein, F.G., Wang, D., Hindupur, S.V., Ehrenfeld, M., Holm, P.S., and Nawroth, R. (2021). Concepts in Oncolytic Adenovirus Therapy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910522"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2174\/156652309789753329","article-title":"\u201cBuy one get one free\u201d: Armed viruses for the treatment of cancer cells and their microenvironment","volume":"9","author":"Kaur","year":"2009","journal-title":"Curr. Gene Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1586\/14760584.2013.836912","article-title":"Oncolytic vaccines","volume":"12","author":"Elsedawy","year":"2013","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"19976","DOI":"10.18632\/oncotarget.5116","article-title":"Going viral: A review of replication-selective oncolytic adenoviruses","volume":"6","author":"Larson","year":"2015","journal-title":"Oncotarget"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Chen, L., Zuo, M., Zhou, Q., and Wang, Y. (2023). Oncolytic virotherapy in cancer treatment: Challenges and optimization prospects. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1308890"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Jiang, B., Zhou, L., Lu, J., Wang, Y., Liu, C., You, L., and Guo, J. (2020). Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.576399"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.chom.2014.01.002","article-title":"Viruses for tumor therapy","volume":"15","author":"Bell","year":"2014","journal-title":"Cell Host Microbe"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: A new era of cancer treatment at dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Yoo, S.Y., Badrinath, N., Lee, H.L., Heo, J., and Kang, D.H. (2019). A Cancer-Favoring, Engineered Vaccinia Virus for Cholangiocarcinoma. Cancers, 11.","DOI":"10.3390\/cancers11111667"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.18632\/oncotarget.27745","article-title":"Targeting desmoplasia in pancreatic cancer as an essential first step to effective therapy","volume":"11","author":"Ebelt","year":"2020","journal-title":"Oncotarget."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.cgh.2008.05.006","article-title":"The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma","volume":"6","author":"Erkan","year":"2008","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.21.02616","article-title":"Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot","volume":"40","author":"Ullman","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ags3.12225","article-title":"Role of the tumor microenvironment in pancreatic cancer","volume":"3","author":"Murakami","year":"2019","journal-title":"Ann. Gastroenterol. Surg."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e004167","DOI":"10.1136\/jitc-2021-004167","article-title":"Remodeling the tumor microenvironment by oncolytic viruses: Beyond oncolysis of tumor cells for cancer treatment","volume":"10","author":"Wang","year":"2022","journal-title":"J. Immunother. Cancer."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Guo, Z.S., Liu, Z., Kowalsky, S., Feist, M., Kalinski, P., Lu, B., Storkus, W.J., and Bartlett, D.L. (2017). Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.00555"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ebiom.2016.06.046","article-title":"Oncolytic Viruses: Therapeutics With an Identity Crisis","volume":"9","author":"Breitbach","year":"2016","journal-title":"eBioMedicine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/978-3-319-67577-0_11","article-title":"Oncolytic Virotherapy and the Tumor Microenvironment","volume":"1036","author":"Berkey","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.molmed.2013.02.008","article-title":"Mounting a strategic offense: Fighting tumor vasculature with oncolytic viruses","volume":"19","author":"Angarita","year":"2013","journal-title":"Trends Mol. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1158\/0008-5472.CAN-12-2687","article-title":"Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans","volume":"73","author":"Breitbach","year":"2013","journal-title":"Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nm.3848","article-title":"Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity","volume":"21","author":"Ilkow","year":"2015","journal-title":"Nat. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.canlet.2017.03.009","article-title":"Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer","volume":"396","author":"Jung","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/gt.2009.142","article-title":"Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy","volume":"17","author":"Choi","year":"2010","journal-title":"Gene Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.canlet.2019.05.033","article-title":"Oncolytic Ad co-expressing decorin and Wnt decoy receptor overcomes chemoresistance of desmoplastic tumor through degradation of ECM and inhibition of EMT","volume":"459","author":"Li","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.omto.2018.01.003","article-title":"Evidence of Anti-tumoral Efficacy in an Immune Competent Setting with an iRGD-Modified Hyaluronidase-Armed Oncolytic Adenovirus","volume":"8","author":"Moreno","year":"2018","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e003254","DOI":"10.1136\/jitc-2021-003254","article-title":"VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects","volume":"9","author":"Laquente","year":"2021","journal-title":"J. Immunother. Cancer."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/jso.24626","article-title":"Oncolytic viral therapy for pancreatic cancer","volume":"116","author":"Rahal","year":"2017","journal-title":"J. Surg. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Dock, G. (1904). The Influence of Complicating Diseases Upon Leukaemia, Lea Brothers & Company.","DOI":"10.1097\/00000441-190412740-00001"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/17460441.2021.1850689","article-title":"The discovery and development of oncolytic viruses: Are they the future of cancer immunotherapy?","volume":"16","author":"Zhang","year":"2021","journal-title":"Expert Opin. Drug. Discov."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1126\/science.1851332","article-title":"Experimental therapy of human glioma by means of a genetically engineered virus mutant","volume":"252","author":"Martuza","year":"1991","journal-title":"Science"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1146\/annurev-cancerbio-030617-050254","article-title":"Oncolytic Herpes Simplex Viruses as a Paradigm for the Treatment of Cancer","volume":"2","author":"Bommareddy","year":"2018","journal-title":"Annu. Rev. Cancer Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5582","DOI":"10.3390\/cimb46060334","article-title":"Targeting Cancers with oHSV-Based Oncolytic Viral Immunotherapy","volume":"46","author":"Nasar","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.omto.2020.11.006","article-title":"Phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for the treatment of metastatic pancreatic cancer","volume":"20","author":"Barton","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2174\/1566523218666180910163805","article-title":"Oncolytic Virotherapy for Breast Cancer Treatment","volume":"18","author":"OBryan","year":"2018","journal-title":"Curr. Gene Ther."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Asija, S., Chatterjee, A., Goda, J.S., Yadav, S., Chekuri, G., and Purwar, R. (2023). Oncolytic immunovirotherapy for high-grade gliomas: A novel and an evolving therapeutic option. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1118246"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/1535-7163.MCT-16-0526","article-title":"Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma","volume":"16","author":"Dai","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jconrel.2015.10.015","article-title":"Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model","volume":"220 Pt B","author":"Na","year":"2015","journal-title":"J. Control Release"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jconrel.2019.04.040","article-title":"Systemic administration of human mesenchymal stromal cells infected with polymer-coated oncolytic adenovirus induces efficient pancreatic tumor homing and infiltration","volume":"305","author":"Na","year":"2019","journal-title":"J. Control Release"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.7150\/thno.40902","article-title":"Oligopeptide-modified poly(beta-amino ester)s-coated AdNuPARmE1A: Boosting the efficacy of intravenously administered therapeutic adenoviruses","volume":"10","author":"Cascante","year":"2020","journal-title":"Theranostics"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"18041","DOI":"10.18632\/oncotarget.24710","article-title":"Combination of interferon-expressing oncolytic adenovirus with chemotherapy and radiation is highly synergistic in hamster model of pancreatic cancer","volume":"9","author":"Salzwedel","year":"2018","journal-title":"Oncotarget"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e99573","DOI":"10.1172\/jci.insight.99573","article-title":"Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses","volume":"3","author":"Watanabe","year":"2018","journal-title":"JCI Insight"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Raimondi, G., Gea-Sorl\u00ed, S., Otero-Mateo, M., and Fillat, C. (2021). Inhibition of miR-222 by Oncolytic Adenovirus-Encoded miRNA Sponges Promotes Viral Oncolysis and Elicits Antitumor Effects in Pancreatic Cancer Models. Cancers, 13.","DOI":"10.3390\/cancers13133233"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1158\/1535-7163.MCT-21-0240","article-title":"Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo","volume":"21","author":"Doerner","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/s41416-024-02583-0","article-title":"Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus","volume":"130","author":"Hashimoto","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.3892\/mmr.2017.6472","article-title":"Synergistic antitumor effects of CDK inhibitor SNS-032 and an oncolytic adenovirus co-expressing TRAIL and Smac in pancreatic cancer","volume":"15","author":"Ge","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e728","DOI":"10.1038\/cddis.2013.259","article-title":"Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer","volume":"4","author":"Carew","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/cgt.2014.40","article-title":"MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus","volume":"21","author":"Baertsch","year":"2014","journal-title":"Cancer Gene Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e1038689","DOI":"10.1080\/2162402X.2015.1038689","article-title":"New role of Interleukin-10 in enhancing the antitumor efficacy of oncolytic vaccinia virus for treatment of pancreatic cancer","volume":"4","author":"Chard","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e003809","DOI":"10.1136\/jitc-2021-003809","article-title":"CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model","volume":"10","author":"Wang","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"200780","DOI":"10.1016\/j.omton.2024.200780","article-title":"Minute virus of mice shows oncolytic activity against pancreatic cancer cells exhibiting a mesenchymal phenotype","volume":"32","author":"Vienne","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Sch\u00e4fer, T.E., Knol, L.I., Haas, F.V., Hartley, A., Pernickel, S.C.S., J\u00e1dy, A., Finkbeiner, M.S.C., Achberger, J., Arelaki, S., and Modic, \u017d. (2024). Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures. eBioMedicine, 105.","DOI":"10.1016\/j.ebiom.2024.105219"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1158\/1078-0432.CCR-14-0464","article-title":"A vaccinia virus armed with interleukin-10 is a promising therapeutic agent for treatment of murine pancreatic cancer","volume":"21","author":"Chard","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ymthe.2018.09.016","article-title":"Bioselection Reveals miR-99b and miR-485 as Enhancers of Adenoviral Oncolysis in Pancreatic Cancer","volume":"27","author":"Raimondi","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1158\/1535-7163.MCT-17-0671","article-title":"The Novel Oncolytic Adenoviral Mutant Ad5-3\u0394-A20T Retargeted to \u03b1v\u03b26 Integrins Efficiently Eliminates Pancreatic Cancer Cells","volume":"17","author":"Man","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e2835","DOI":"10.1038\/cddis.2017.230","article-title":"RGD-modified oncolytic adenovirus-harboring shPKM2 exhibits a potent cytotoxic effect in pancreatic cancer via autophagy inhibition and apoptosis promotion","volume":"8","author":"Xu","year":"2017","journal-title":"Cell Death Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10495-015-1208-z","article-title":"Survivin silencing and TRAIL expression using oncolytic adenovirus increase anti-tumorigenic activity in gemcitabine-resistant pancreatic cancer cells","volume":"21","author":"Han","year":"2016","journal-title":"Apoptosis"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.virol.2015.08.003","article-title":"Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1","volume":"485","author":"Cataldi","year":"2015","journal-title":"Virology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.omto.2021.04.015","article-title":"MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer","volume":"21","author":"Singh","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/emmm.201302796","article-title":"Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas","volume":"5","author":"Li","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.canlet.2013.11.007","article-title":"Oncolytic vaccinia virus in combination with radiation shows synergistic antitumor efficacy in pancreatic cancer","volume":"344","author":"Dai","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Seidel, J.A., Otsuka, A., and Kabashima, K. (2018). Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00086"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Palanivelu, L., Liu, C.H., and Lin, L.T. (2023). Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1038226"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.7150\/thno.83495","article-title":"OX40L-Armed Oncolytic Virus Boosts T-cell Response and Remodels Tumor Microenvironment for Pancreatic Cancer Treatment","volume":"13","author":"Liu","year":"2023","journal-title":"Theranostics"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e003923","DOI":"10.1136\/jitc-2021-003923","article-title":"Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression","volume":"10","author":"Nelson","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/sj.gt.3301398","article-title":"Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: A phase I trial","volume":"8","author":"Mulvihill","year":"2001","journal-title":"Gene Ther."},{"key":"ref_91","first-page":"555","article-title":"A phase I\/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma","volume":"9","author":"Hecht","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.canlet.2018.07.006","article-title":"Advances in oncolytic adenovirus therapy for pancreatic cancer","volume":"434","author":"Nattress","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e003255","DOI":"10.1136\/jitc-2021-003255","article-title":"Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors","volume":"10","author":"Macarulla","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S1470-2045(24)00079-2","article-title":"LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): Results from arm 1 of a non-randomised, single-centre, phase 1\/2 study","volume":"25","author":"Musher","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/mt.2016.66","article-title":"Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma","volume":"24","author":"Noonan","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/j.ymthe.2024.04.029","article-title":"Oncolytic adenovirus in treating malignant ascites: A phase II trial and longitudinal single-cell study","volume":"32","author":"Zhang","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e15753","DOI":"10.1200\/JCO.2017.35.15_suppl.e15753","article-title":"A study of REOLYSIN in combination with pembrolizumab and chemotherapy in patients (pts) with relapsed metastatic adenocarcinoma of the pancreas (MAP)","volume":"35","author":"Mahalingam","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1158\/1078-0432.CCR-19-2078","article-title":"Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study","volume":"26","author":"Mahalingam","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1200\/JCO.2023.41.16_suppl.2569","article-title":"A phase 1 first-in-human study of interferon beta (IFN\u03b2) and membrane-stable CD40L expressing oncolytic virus (MEM-288) in solid tumors including non\u2013small-cell lung cancer (NSCLC)","volume":"41","author":"Saltos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_100","first-page":"A861","article-title":"766\u2005A clinical trial to evaluate the safety, tolerability and preliminary efficacy of VG161 in combination with Nivolumab in patients with advanced pancreatic cancer","volume":"11","author":"Shen","year":"2023","journal-title":"J. ImmunoTherapy Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/sj.gt.3302459","article-title":"Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression","volume":"12","author":"Pipiya","year":"2005","journal-title":"Gene Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"8117","DOI":"10.1007\/s00432-023-04735-w","article-title":"Oncolytic adenoviruses and the treatment of pancreatic cancer: A review of clinical trials","volume":"149","author":"Taylor","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Bhatnagar, A.R., Siddiqui, F., Khan, G., Pompa, R., Kwon, D., and Nyati, S. (2024). Long-Term Follow-Up of Phase I Trial of Oncolytic Adenovirus-Mediated Cytotoxic and Interleukin-12 Gene Therapy for Treatment of Metastatic Pancreatic Cancer. Biomedicines, 12.","DOI":"10.3390\/biomedicines12051065"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2023.01.002","article-title":"Preexisting immunity: Barrier or bridge to effective oncolytic virus therapy?","volume":"70","author":"Groeneveldt","year":"2023","journal-title":"Cytokine Growth Factor. Rev."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/jcb.25917","article-title":"Interferon-Mediated Tumor Resistance to Oncolytic Virotherapy","volume":"118","author":"Ebrahimi","year":"2017","journal-title":"J. Cell Biochem."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/jnci\/djy033","article-title":"Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy","volume":"110","author":"Kurokawa","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e2303907","DOI":"10.1002\/advs.202303907","article-title":"Erythrocyte-Leveraged Oncolytic Virotherapy (ELeOVt): Oncolytic Virus Assembly on Erythrocyte Surface to Combat Pulmonary Metastasis and Alleviate Side Effects","volume":"11","author":"Liu","year":"2024","journal-title":"Adv. Sci."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Bounassar-Filho, J.P., Boeckler-Troncoso, L., Cajigas-Gonzalez, J., and Zavala-Cerna, M.G. (2023). SARS-CoV-2 as an Oncolytic Virus Following Reactivation of the Immune System: A Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032326"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1099\/vir.0.043281-0","article-title":"Extracellular matrix constituents interfere with Newcastle disease virus spread in solid tissue and diminish its potential oncolytic activity","volume":"93","author":"Yaacov","year":"2012","journal-title":"J. Gen. Virol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12935-024-03424-z","article-title":"Enhancing cancer therapy: The integration of oncolytic virus therapy with diverse treatments","volume":"24","author":"Yan","year":"2024","journal-title":"Cancer Cell Int."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12943-022-01664-z","article-title":"Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways","volume":"21","author":"Zhu","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1158\/1078-0432.CCR-21-0660","article-title":"Can Biomarkers Guide Oncolytic Virus Immunotherapy?","volume":"27","author":"Kaufman","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00280-017-3260-6","article-title":"A phase II study of REOLYSIN\u00ae (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma","volume":"79","author":"Mahalingam","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.omto.2019.10.007","article-title":"Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances","volume":"15","author":"Zheng","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41392-022-00951-x","article-title":"Engineering strategies to enhance oncolytic viruses in cancer immunotherapy","volume":"7","author":"Tian","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"0108","DOI":"10.34133\/research.0108","article-title":"Emerging Nano-\/Biotechnology Drives Oncolytic Virus-Activated and Combined Cancer Immunotherapy","volume":"6","author":"Fang","year":"2023","journal-title":"Research"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"103980","DOI":"10.1016\/j.critrevonc.2023.103980","article-title":"Nano based-oncolytic viruses for cancer therapy","volume":"185","author":"Akhoondi","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Li, Z., Jiang, Z., Zhang, Y., Huang, X., and Liu, Q. (2020). Efficacy and Safety of Oncolytic Viruses in Randomized Controlled Trials: A Systematic Review and Meta-Analysis. Cancers, 12.","DOI":"10.3390\/cancers12061416"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3770","article-title":"Going viral with cancer immunotherapy","volume":"14","author":"Lichty","year":"2014","journal-title":"Nat. Rev. Cancer."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.csbj.2014.11.005","article-title":"Machine learning applications in cancer prognosis and prediction","volume":"13","author":"Kourou","year":"2014","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_121","unstructured":"Ennaji, M.M. (2023). Chapter 4\u2014Oncolytic virus cancer therapeutic options and integration of artificial intelligence into virus cancer research. Oncogenic Viruses, Academic Press."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/18\/9912\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:55:59Z","timestamp":1760111759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/18\/9912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":121,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["ijms25189912"],"URL":"https:\/\/doi.org\/10.3390\/ijms25189912","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,13]]}}}